Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
APIs | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Scale-up/Technology Transfer
Cambrex Invests $5M in New Lab Expansion
To add capability and capacity at Karlskoga, Sweden facility05.31.18
-
APIs | Cytotoxics and High Potency Manufacturing | Drug Development | Industry News
Cambrex Completes Pilot Plant Expansion at High Point
Begins construction of a new $24 million facility at Charles City, IA plant for the manufacture of HPAPIs05.15.18
-
Cytotoxics and High Potency Manufacturing | Industry News
PCI Launches High Containment Packaging at Ireland Site
Latest strategic initiative expands High Containment Operations services04.25.18
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Idifarma Expands High Potent Capabilities
Niche CDMO adds spray drying for highly potent drugs03.29.18
-
Analytical Services | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
PCI Bolsters Analytical Capabilities
Significant expansion of analytical laboratories at its center of excellence for contained manufacturing03.20.18
-
Analytical Services | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Formulation Development | Industry News | Solid Dosage/Creams/Ointments
Hovione Expands Capacity
Plans for future expansion at its sites in Portugal, Ireland and New Jersey03.19.18
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Solid Dosage/Creams/Ointments
Lonza Expands Encapsulation and HPAPI Capabilities in North America
A new suite added that facilitates encapsulation of highly potent compounds02.21.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Avista Doubles API Mfg. Capacity at Colorado Facility
Upgrades support processing of potent compounds11.17.17
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
PCI Expands Highly Potent Capabilities for Clinical Services
Makes another investment in fully contained Xcelodose 600S technology11.10.17
-
Breaking News | Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Capsugel Expands Capabilities
To offer more clinical trial services as well as high potency compounds11.01.17
-
Breaking News | Cytotoxics and High Potency Manufacturing | Drug Development | Facilities | Industry News | Inspections | Solid Dosage/Creams/Ointments
Almac Passes MHRA Inspection at Charnwood Facilities
Can develop, make and pack non-potent and potent, solid orals for clinical trials and commercial supply10.23.17
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Solid Dosage/Creams/Ointments
Pfizer CentreOne Expands Contract Mfg. to Nagoya, Japan
Site will provide in-country manufacture of highly potent oral solid dosage forms10.23.17
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
CordenPharma Acquires Pfizer API Mfg. Facility
54,000 square foot facility has production capabilities ranging from very small-scale up to 3,000 liters10.12.17
-
Bioanalytical Services | Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Drug Development | Facilities | Process Development | Scale-up/Technology Transfer
ADC Bio Invests $11M in Bioconjugation Facility
Will provide capabilities and R&D technical services from process development through to manufacturing09.25.17
-
Biologics, Proteins, Vaccines | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Cambrex Expands HPAPI Footprint
Invests $24 million in new highly potent API manufacturing capacity at its Charles City, IA facility08.09.17
-
Cytotoxics and High Potency Manufacturing
High Potency APIs: Some Bad News, Some Good News
The growing use of HPAPIs has created some challenges in the lab, while at the same time offering advantages as well.Emil W. Ciurczak, DoraMaxx Consulting 07.18.17
-
Breaking News | cGMP Manufacture | Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Industry News
Mayne Pharma, Metrics Contract Services Designate CoE
The 17,000 sq.-ft. CoE triples the company’s previous stability storage capacity07.11.17
-
APIs | Bioanalytical Services | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
-
Cytotoxics and High Potency Manufacturing
